which exhibit low oral bioavailability, companies are frequently faced with the choice to either develop or discard the early stage compound. In order to expedite this decision, the question of alter- native delivery technologies needs to be discussed in the early stages of drug development. For certain drugs that (i) have a broad therapeutic window, (ii) require a low daily dose, and (iii) are going to be used for the long-term treatment of disease, injectable con- trolled release depots such as drug-loaded biodegradable polymer microparticles, may provide such an alternative delivery strategy, potentially rescuing an otherwise undeliverable drug.